concanavalin a (InvivoGen)
Structured Review
Concanavalin A, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 32 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cona/Concanavalin+A/pmc13390583-61-19-22
Average 97 stars, based on 32 article reviews
Images
Related Articles
Control:Article Title: nELISA: a high-throughput, high-plex platform enables quantitative profiling of the inflammatory secretome Article Snippet: For stimulation conditions, Article Title: Pharmacological Wnt Ligand Inhibition Overcomes Key Tumor-Mediated Resistance Pathways to Anti-PD-1 Immunotherapy Article Snippet: Authors: Nicholas C. DeVito1, Michael Sturdivant1, Christine Xiao1, Balamayooran Thievanthiran1, Michael P. Plebanek1, April K.S.. Salama1, Georgia M. Beasley2, Alisha Holtzhausen3, Veronica Novotny-Diermayr4, John H. Strickler1, Brent A. Hanks1,5 Affiliations: 1Department of Medicine Division of Medical Oncology Duke University Medical Center Duke Cancer Institute Durham, NC 27710 2Department of Surgery Division of Surgical Oncology Duke University Medical Center Duke Cancer Institute Durham, NC 27710 3Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill, NC 27599 USA 4Experimental Drug Development Centre (EDDC), A*STAR 10 Biopolis Road #05-01 Chromos Singapore 138670 5Department of Pharmacology and Cancer Biology Duke University Durham, NC 27708 Lead Contact: Brent A. Hanks, brent.hanks@duke.edu This preprint research paper has not been peer reviewed.. Electronic copy available at: https://ssrn.com/abstract=3713445 Pr ep rin t ot p ee r r ev ie we d 2 Negative Control:Article Title: nELISA: a high-throughput, high-plex platform enables quantitative profiling of the inflammatory secretome Article Snippet: For stimulation conditions, Article Title: Pharmacological Wnt Ligand Inhibition Overcomes Key Tumor-Mediated Resistance Pathways to Anti-PD-1 Immunotherapy Article Snippet: Authors: Nicholas C. DeVito1, Michael Sturdivant1, Christine Xiao1, Balamayooran Thievanthiran1, Michael P. Plebanek1, April K.S.. Salama1, Georgia M. Beasley2, Alisha Holtzhausen3, Veronica Novotny-Diermayr4, John H. Strickler1, Brent A. Hanks1,5 Affiliations: 1Department of Medicine Division of Medical Oncology Duke University Medical Center Duke Cancer Institute Durham, NC 27710 2Department of Surgery Division of Surgical Oncology Duke University Medical Center Duke Cancer Institute Durham, NC 27710 3Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill, NC 27599 USA 4Experimental Drug Development Centre (EDDC), A*STAR 10 Biopolis Road #05-01 Chromos Singapore 138670 5Department of Pharmacology and Cancer Biology Duke University Durham, NC 27708 Lead Contact: Brent A. Hanks, brent.hanks@duke.edu This preprint research paper has not been peer reviewed.. Electronic copy available at: https://ssrn.com/abstract=3713445 Pr ep rin t ot p ee r r ev ie we d 2 |
